

Zhe Liu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3684552/publications.pdf>

Version: 2024-02-01

36
papers

605
citations

623699

14
h-index

642715

23
g-index

42
all docs

42
docs citations

42
times ranked

913
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. <i>Lung Cancer</i> , 2014, 83, 231-239.	2.0	99
2	Upregulated NNT-AS1, a long noncoding RNA, contributes to proliferation and migration of colorectal cancer cells in vitro and in vivo. <i>Oncotarget</i> , 2017, 8, 3441-3453.	1.8	55
3	MicroRNA-375 suppresses human colorectal cancer metastasis by targeting Frizzled 8. <i>Oncotarget</i> , 2016, 7, 40644-40656.	1.8	46
4	Aberrant O ⁶ -glycosylation contributes to tumorigenesis in human colorectal cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 4875-4885.	3.6	45
5	Tn antigen promotes human colorectal cancer metastasis via H ¹ ERas mediated epithelial ¹ mesenchymal transition activation. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 2083-2092.	3.6	37
6	A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. <i>Lung Cancer</i> , 2020, 147, 259-268.	2.0	31
7	Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1403-1414.	1.1	26
8	T-Synthase Deficiency Enhances Oncogenic Features in Human Colorectal Cancer Cells via Activation of Epithelial-Mesenchymal Transition. <i>BioMed Research International</i> , 2018, 2018, 1-7.	1.9	24
9	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non ¹ Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1207-1217.	1.6	23
10	CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2018, 40, 2023-2035.	2.6	23
11	Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. <i>Lung Cancer</i> , 2020, 149, 154-161.	2.0	21
12	Genome-wide analysis of the hypoxia-related DNA methylation-driven genes in lung adenocarcinoma progression. <i>Bioscience Reports</i> , 2020, 40, .	2.4	21
13	Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2289-2295.	2.0	19
14	Overexpression of NNT-AS1 Activates TGF- ¹ 2 Signaling to Decrease Tumor CD4 Lymphocyte Infiltration in Hepatocellular Carcinoma. <i>BioMed Research International</i> , 2020, 2020, 1-11.	1.9	18
15	Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma ¹ induced malignant pleural effusion. <i>Thoracic Cancer</i> , 2018, 9, 298-304.	1.9	15
16	Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People ¹ s Republic of China. <i>Journal of Thoracic Oncology</i> , 2022, 17, 816-826.	1.1	15
17	Analysis of clinical characteristics and prognosis of patients with anaplastic lymphoma kinase ¹ positive and surgically resected lung adenocarcinoma. <i>Thoracic Cancer</i> , 2017, 8, 8-15.	1.9	13
18	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung ¹ A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1743-1749.	1.1	13

#	ARTICLE	IF	CITATIONS
19	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer â€” The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	2.0	12
20	<sc>ALK</sc>â€”rearranged squamous cell carcinoma of the lung. <i>Thoracic Cancer</i> , 2021, 12, 1106-1114.	1.9	12
21	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	2.8	7
22	Granzyme Bâ€”Producing B Cells Function as a Feedback Loop for T Helper Cells in Liver Transplant Recipients with Acute Rejection. <i>Inflammation</i> , 2021, 44, 2270-2278.	3.8	6
23	Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 622142.	2.8	5
24	Efficacy and safety of bevacizumab in advanced lung adenocarcinoma patients with stable disease after two cycles of firstâ€”line chemotherapy: A multicenter prospective cohort study. <i>Thoracic Cancer</i> , 2020, 11, 3641-3644.	1.9	4
25	Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. <i>Diagnostic Pathology</i> , 2022, 17, 27.	2.0	3
26	Application of Rapid Rehabilitation Surgical Nursing Combined With Continuous Nursing in Self-Care Ability, Medication Compliance and Quality of Life of Renal Transplant Patients. <i>Frontiers in Surgery</i> , 2022, 9, 844533.	1.4	3
27	P2.03b-010 EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S938-S939.	1.1	1
28	P3.02c-020 More Than 3 Years Long-Term Maintenance Treatment of Bevacizumab for Advanced-Stage NSCLC: A Report of Three Cases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1284.	1.1	1
29	Tislelizumab, an investigational anti-PD-1 antibody, combined with chemotherapy as first-line treatment for lung cancer in Chinese patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14067-e14067.	1.6	1
30	Ratio of CA19-9 Level to Total Tumor Volume as a Prognostic Predictor of Pancreatic Carcinoma After Curative Resection. <i>Technology in Cancer Research and Treatment</i> , 2022, 21, 153303382210784.	1.9	1
31	Neoadjuvant atelizumab combined chemotherapy in limited-stage and resectable small cell lung cancer: A multicentric, single-arm and open study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e20615-e20615.	1.6	1
32	P3.02c-016 Efficacy of Bevacizumab Combined with Chemotherapy in Lung Adenocarcinoma-Induced Malignant Pleural Effusion. <i>Journal of Thoracic Oncology</i> , 2017, 12, S1281-S1282.	1.1	0
33	JCES01.23 EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2017, 12, S240.	1.1	0
34	OA11.03 A Randomized, Multi-Center, Double-Blind Phase II Study of Fruquintinib in Patients with Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S286.	1.1	0
35	Overexpression of fibrinogen-like protein 2 alleviates acute rejection in rat models of liver transplantation. <i>Annals of Translational Medicine</i> , 2021, 9, 408-408.	1.7	0
36	Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: A systematic review and meta-analysis of clinical trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19149-e19149.	1.6	0